15.40Open15.40Pre Close0 Volume221 Open Interest240.00Strike Price0.00Turnover40.65%IV0.94%PremiumDec 20, 2024Expiry Date13.01Intrinsic Value100Multiplier18DDays to Expiry2.39Extrinsic Value100Contract SizeAmericanOptions Type0.7447Delta0.0142Gamma14.75Leverage Ratio-0.2279Theta0.0831Rho10.99Eff Leverage0.1790Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet